# Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL

> **NCT07443488** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- HSCT
- Ph+ ALL

## Interventions

- **DRUG:** Olverembatinib+INO

## Key facts

- **NCT ID:** NCT07443488
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-14
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443488, "Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07443488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*